Form 8-K - Current report:
SEC Accession No. 0000950170-23-009483
Filing Date
2023-03-23
Accepted
2023-03-23 16:07:41
Documents
14
Period of Report
2023-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atha-20230323.htm   iXBRL 8-K 62041
2 EX-99.1 atha-ex99_1.htm EX-99 195709
3 GRAPHIC img247042425_0.jpg GRAPHIC 18091
  Complete submission text file 0000950170-23-009483.txt   418413

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atha-20230323_pre.xml EX-101.PRE 11413
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atha-20230323_lab.xml EX-101.LAB 13896
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atha-20230323.xsd EX-101.SCH 2446
8 EXTRACTED XBRL INSTANCE DOCUMENT atha-20230323_htm.xml XML 4888
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

EIN.: 453368487 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39503 | Film No.: 23756257
SIC: 2836 Biological Products, (No Diagnostic Substances)